ARCH
Startup rounds since 2012 with a ARCH investor on the board, and the firm's own fund filings.
Raises
144
since 2012
Unannounced
3
no announcement found, of those filed since 2025
Funds
10
fund filings under the firm's name
Rounds
- SonoThera, Inc.$125M
- Ollin Biosciences, Inc.$156M
- Vizgen, Inc.$47.8M
- Pheast Therapeutics, Inc.$24.6M
- Vizgen, Inc.$3.5M
- Treeline Biosciences, Inc.$200M
- OncoResponse, Inc$6M
- Pheast Therapeutics, Inc.$75.2M
- Areteia Therapeutics, Inc.$360M
- Proniras Corp$6.93M
- Cytrellis Biosystems, Inc.$25.1M
- Metsera, Inc.$215M
- Seaport Therapeutics, Inc.$226M
- Treeline Biosciences, Inc.$422M
- RIPPL Care, Inc.$23M
- Autobahn Therapeutics, Inc.$101M
- Ultivue, Inc.$3.32M
- Mirador Therapeutics, Inc.$333M
- Mirador Therapeutics, Inc.$80M
- eGenesis, Inc.$25.4M
- Elephas Biosciences Corp$51.2M
- Boundless Bio, Inc.$100M
- OncoResponse Inc$13.9M
- SonoThera, Inc.$30.4M
- Faraday Pharmaceuticals, Inc.$52.8M
- hC Bioscience, Inc.$20M
- Treeline Biosciences, Inc.$261M
- Elephas Biosciences Corp$41.5M
- IngredientWerks, Inc.$750K
- Vizgen, Inc.$85.2M
- Apex Neuro Holdings, Inc.$4M
- Arbor Biotechnologies, Inc.$215M
- Nutcracker Therapeutics, Inc.$144M
- Medical Creations, Inc.$7.72M
- Boundless Bio, Inc.$106M
- Treeline Biosciences, Inc.$212M
- Vizgen, Inc.$37M
- OncoResponse Inc$40.6M
- eGenesis, Inc.$125M
- Vividion Therapeutics, Inc.$135M
- National Resilience, Inc.$755M
- Cytrellis Biosystems, Inc.$50M
- Sana Biotechnology, Inc.$45.9M
- Insitro, Inc.$143M
- Nutcracker Therapeutics, Inc.$14M
- Grail, Inc.$388M
- Boundless Bio, Inc.$23.2M
- Apex Neuro Holdings, Inc.$20M
- eGenesis, Inc.$100M
- Faraday Pharmaceuticals, Inc.$25.1M
By year
| Year | Raises | Unannounced |
|---|---|---|
| 2026 | 3 | 0 |
| 2025 | 7 | 3 |
| 2024 | 11 | None yet |
| 2023 | 2 | None yet |
| 2022 | 8 | None yet |
| 2021 | 11 | None yet |
| 2020 | 5 | None yet |
| 2019 | 10 | None yet |
| 2018 | 17 | None yet |
| 2017 | 19 | None yet |
| 2016 | 13 | None yet |
| 2015 | 17 | None yet |
| 2014 | 15 | None yet |
| 2012 | 6 | None yet |
Raises are checked for an announcement from 2025 on.
Funds
The firm's own fund filings, newest first, each at its latest filing.
| Fund | Filed | Size | Raised |
|---|---|---|---|
| ARCH Venture Fund XIV, L.P. | 31 Aug 2026 | $3B | None |
| ARCH Venture Fund XIII, L.P. | 1 Feb 2024 | $3B | None |
| ARCH Venture Fund XII, L.P. | 1 Apr 2022 | $2.91B | $2.81B |
| ARCH Venture Fund XI, L.P. | 28 Jan 2021 | $1.85B | $1.85B |
| ARCH Venture Fund X, L.P. | 25 Oct 2019 | $675M | $636M |
| ARCH Venture Fund X Overage, L.P. | 25 Oct 2019 | $675M | $636M |
| ARCH Venture Fund IX, L.P. | 18 Nov 2016 | $550M | $408M |
| ARCH Venture Fund IX Overage, L.P. | 18 Nov 2016 | $450M | None |
| ARCH Venture Fund VIII Overage, L.P. | 6 Mar 2015 | $150M | None |
| ARCH Venture Fund VIII, L.P. | 27 Aug 2014 | $401M | $401M |
Listed because a ARCH fund's filing names a director of each company. A name match is not a verified identity.